We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy

By LabMedica International staff writers
Posted on 20 May 2026

Peripheral neuropathy is a common neurological disorder that causes pain, sensory loss, imbalance, and weakness, affecting an estimated 12%–20% of people in the U. More...

S. and nearly 30% of adults over age 65. Because many cases remain unexplained and standard genetic testing often misses disease-causing repeat expansions in the RFC1 gene, researchers have developed a machine learning–enabled computational approach to identify these expansions and clarify their role in idiopathic neuropathy.

Researchers at Washington University (St. Louis, MO, USA) and collaborating institutions developed a novel computational tool that couples a genome-sequencing pipeline with machine learning to reliably identify and classify RFC1 repeat expansions. The method focuses on expansions of the DNA motif AAGGG that extend far beyond normal length and are difficult to detect with standard genetic testing methods. By analyzing genome sequencing data, the approach distinguishes pathogenic repeat expansions with improved reliability for use across clinical and research workflows.

Using this approach, the investigators found that RFC1 repeat expansions may account for more than 2% of idiopathic peripheral neuropathy. The finding addresses a persistent diagnostic gap in unexplained neuropathy, where repeat expansions can be missed by conventional assays. The study further indicates that broader genetic testing is warranted for people with unexplained peripheral neuropathy, including those presenting with muscle weakness as well as sensory symptoms.

The work is published in Annals of Neurology. According to the researchers, the tool offers a more affordable and reliable way to interrogate this complex genetic variation in both clinical and research settings. The team has released the tool publicly on GitHub, which could expand access to testing, support more accurate diagnoses, and provide families with clearer information on the genetic causes of their condition.

Related Links
WashU Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.